Advances in nanotechnology for the therapy of bacterial pneumonia
Abstract
Bacterial pneumonia, a life-threatening infection, is the world's sixth deadliest disease and the top cause of mortality in children under five. Without timely treatment, bacterial pneumonia can escalate to a 30% mortality rate, particularly in high-risk populations. It may also lead to chronic conditions such as pulmonary fibrosis and chronic obstructive pulmonary disease(COPD), along with systemic inflammatory responses that can progress to sepsis and multi-organ failure. Although antibiotics are generally effective against bacterial pneumonia, current treatment approaches remain insufficient due to several barriers, including the lung's unique mucus barrier, low pH, high oxidative stress, disruption of alveolar surfactants, and accumulation of hypertonic fluid on the airway surface. In addition, following the excessive use of antibiotics, dysbiosis, secondary infections and resistance occur. Nanomaterials can be an effective way to improve therapeutic effects owing to their change on drug size, physicochemical properties, hydrophobicity along with better targeting ability, and controlled localized release. Organic and inorganic substances and their composites are the three main types of nanomaterials to treat bacterial pneumonia. This review presents the latest advancements and constraints of these nanomaterials from a nanotechnology viewpoint with a view to developing therapeutic strategies for bacterial pneumonia.
Read the paper
Related studies
- Structural and topological analysis of thiosemicarbazone-based metal complexes: computational and experimental study of bacterial biofilm inhibition and antioxidant activity
- Toward better cures for Mycobacterium abscessus lung disease
- Challenges for global antibiotic regimen planning and establishing antimicrobial resistance targets: implications for the WHO Essential Medicines List and AWaRe antibiotic book dosing
- Design, Synthesis and In vitro Antitubercular Effect of New Chalcone Derivatives Coupled with 1,2,3‐Triazoles: A Computational Docking Techniques
- Upregulation of pmrA, pmrB, pmrC, phoQ, phoP, and arnT genes contributing to resistance to colistin in superbug Klebsiella pneumoniae isolates from human clinical samples in Tehran, Iran
- Whole-genome sequencing of clinical isolates of Citrobacter Europaeus in China carrying blaOXA−48 and blaNDM−1
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.